Crinetics Pharmaceuticals (NYSE: CRNX) — Perfil da empresa, notícias e dados financeiros
Crinetics Pharmaceuticals develops innovative treatments for endocrine diseases through nonpeptide therapeutics.
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals (NASDAQ:CRNX) focuses on discovering, developing, and commercializing innovative treatments for endocrine diseases and endocrine-related tumors. The company is rigorously working on a diverse pipeline of product candidates aimed at addressing unmet medical needs in conditions such as acromegaly, Cushing's disease, and congenital hyperinsulinism through nonpeptide, orally available therapeutics. With a deep commitment to science and patient care, Crinetics Pharmaceuticals is dedicated to advancing new therapies that can significantly improve the lives of those battling endocrine conditions. Their objective is to lead the way in endocrine disease management by providing patients with more effective and convenient treatment options.
Resumo
Operações
Produtos e/ou serviços de Crinetics Pharmaceuticals
- Paltusotine, a nonpeptide somatostatin receptor agonist targeting acromegaly and neuroendocrine tumors.
- CRN04777, an oral somatostatin receptor type 5 agonist for congenital hyperinsulinism.
- CRN04894, an adrenocorticotropic hormone antagonist for Cushing's disease.
- CRN01941, an oral nonpeptide somatostatin receptor type 2 biased agonist for acromegaly.
- Development of therapies for hyperparathyroidism, focusing on calcium sensing receptor agonists.
- Exploration of novel treatments for rare endocrine diseases, including those affecting the thyroid and adrenal glands.
equipe executiva do Crinetics Pharmaceuticals
- Dr. R. Scott Struthers Ph.D.Founder, President, CEO & Director
- Dr. Stephen F. Betz Ph.D.Co-Founder & Chief Scientific Officer
- Mr. Jeff E. Knight M.P.H.Chief Development & Operating Officer
- Mr. Tobin C. SchilkeChief Financial Officer
- Ms. Gayathri DiwakarSenior Director of Investor Relations
- Ms. Garlan Adams J.D.Chief Legal Officer & Corporate Secretary
- Ms. Adriana Cabre M.B.A.Chief Human Resources Officer
- Dr. Alan S. Krasner M.D.Chief Endocrinologist
- Mr. Kevin CappsHead of Intellectual Property
- Mr. Chris Robillard M.B.A.Chief Business Officer
Principais indicadores financeiros
Resultados divulgados pela Crinetics Pharmaceuticals, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,7 mi | -516,8 mi | -465,3 mi | |
| 1 mi | -338,9 mi | -298,4 mi | |
| 4 mi | -222,6 mi | -214,5 mi | |
| 4,7 mi | -167,9 mi | -160 mi |